RecruitingNot ApplicableNCT07097818

Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2

Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2: a Multicentre, Cluster-randomized, Controlled Trial

Sponsor

Second Xiangya Hospital of Central South University

Enrollment

400 participants

Start Date

Aug 18, 2025

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes

Summary

The GLITTER Study 2 is a cluster randomized trial that will evaluate the impact of comprehensive and intensive management, comprising a team, technology, education, and peer resources, on metabolic control and psychological outcomes in patients with type 1 diabetes.

Eligibility

Min Age: 6 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a technology-powered diabetes management program for children and adults with type 1 diabetes in China. It combines continuous glucose monitoring, insulin pumps, remote check-ins, and structured diabetes education to see if blood sugar control improves better than with standard care. **You may be eligible if...** - You have type 1 diabetes - You are 6 years or older - You have had diabetes for more than 3 months - You are willing to use a glucose monitor and insulin pump and share data remotely - You are able to attend follow-up visits at the study hospital over the next year **You may NOT be eligible if...** - You have used an automated insulin delivery system in the last 3 months - You have serious heart, kidney, liver, or thyroid disease - You are pregnant, breastfeeding, or planning to become pregnant within 1 year - You have a skin condition that would prevent wearing a glucose sensor or insulin pump - You have a hearing or vision impairment that would prevent device use - You are currently in another clinical study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALT1D team, structured education, peer support , and diabetes technologies

Patients with T1D will use insulin pumps and CGM , while undergoing structured education courses under the management of a specialized T1D team and engaging in peer support activities.

BEHAVIORALRoutine Management

Patients with T1D will be managed according to the routine diagnosis and education model of each hospital.

Locations(10)

Department of Endocrinology and Metabolism, Peking University People's Hospital

Beijing, Beijing Municipality, China

Department of Endocrinology, Quanzhou First Hospital Affiliated to Fujian Medical University

Quanzhou, Fujian, China

Department of Endocrinology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University

Shenzhen, Guangdong, China

Second Department of Endocrinology and Metabolism, Tangshan Gongren Hospital

Tangshan, Hebei, China

Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology

Luoyang, Henan, China

Department of Endocrinology, Zhongnan Hospital of Wuhan University

Wuhan, Hubei, China

Institute of Metabolism and Endocrinology, Second Xiangya Hospital of Centra South University

Changsha, Hunan, China

Department of Endocrinology and Metabolism, Institute of Endocrinology, The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, China

Department of Endocrinology and Metabolism, Laboratory of Diabetes and metabolism research, West China Hospital, Sichuan University

Chengdu, Sichuan, China

Department of Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07097818

Related Trials

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

NCT072937151 location

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

NCT073413731 location

Prebiotics in Patients With Type 1 Diabetes

NCT049637773 locations

Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)

NCT074575804 locations

Long-Term Outcomes of Teplizumab in Routine Clinical Care

NCT073600802 locations